Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Radiopharm Theranostics Limited (AU:RAD)
ASX:RAD
Holding AU:RAD?
Track your performance easily
RAD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.09
Previous CloseN/A
Volume5.13M
Average Volume (3M)15.03M
Market Cap
AU$59.42M
Enterprise Value-AU$2.38M
Total Cash (Recent Filing)$26.98M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Feb 26, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding2,200,646,700
10 Day Avg. Volume17,950,810
30 Day Avg. Volume15,033,823
Standard Deviation0.20
R-Squared0.05
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2760.01
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-269.63
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.40Price Target Upside1233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Radiopharm Theranostics Limited News
PremiumCompany Announcements
Lantheus Omega Increases Stake in Radiopharm Theranostics
PremiumCompany Announcements
Radiopharm Theranostics Issues New Shares in Compliance with Corporations Act
PremiumCompany Announcements
Radiopharm Theranostics Expands Market Presence with New Securities Quotation
PremiumCompany Announcements
Radiopharm Strengthens Ties with Lantheus Through $5 Million Investment
PremiumCompany Announcements
Radiopharm Partners with Lantheus to Advance Oncology TreatmentsBulls Say, Bears Say
Bulls Say
FDA ApprovalThe FDA approved the Investigational New Drug application for a Phase IIb imaging trial of RAD 101 in brain metastases.
Market ExpansionRadiopharm announced the launch of American Depository Shares, which will be traded in the U.S. over-the-counter market as RADTY, with plans for a secondary listing on Nasdaq.
Therapeutic Pipeline StrategyRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited or no use in radiopharmaceuticals, designed to de-risk development and limit competition.
Bears Say
Capital RaisingThe AUD 70M capital raised resulted in substantially higher dilution than previously estimated.
Financial PerformanceThe ~AUD 70M capital that Radiopharm raised was necessary to fund operations and support the company's ongoing clinical development efforts, the associated prices were lower than previous estimates and, consequently, resulted in substantially higher dilution.
Stock DilutionThe ~AUD 70M capital that Radiopharm raised was necessary to fund operations and support the company's ongoing clinical development efforts, but the associated prices were lower than previous estimates, resulting in substantially higher dilution.
---
Options Prices
Currently, No data available
---
Ownership Overview
RAD FAQ
What was Radiopharm Theranostics Limited’s price range in the past 12 months?
Radiopharm Theranostics Limited lowest share price was AU$0.02 and its highest was AU$0.09 in the past 12 months.
What is Radiopharm Theranostics Limited’s market cap?
Radiopharm Theranostics Limited’s market cap is AU$59.42M.
When is Radiopharm Theranostics Limited’s upcoming earnings report date?
Radiopharm Theranostics Limited’s upcoming earnings report date is Feb 26, 2025 which is in 35 days.
How were Radiopharm Theranostics Limited’s earnings last quarter?
Radiopharm Theranostics Limited released its earnings results on Aug 29, 2024. The company reported -AU$0.052 earnings per share for the quarter, missing the consensus estimate of -AU$0.01 by -AU$0.042.
Is Radiopharm Theranostics Limited overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Undervalued.
Does Radiopharm Theranostics Limited pay dividends?
Radiopharm Theranostics Limited does not currently pay dividends.
What is Radiopharm Theranostics Limited’s EPS estimate?
Radiopharm Theranostics Limited’s EPS estimate is -0.01.
How many shares outstanding does Radiopharm Theranostics Limited have?
Radiopharm Theranostics Limited has 2,200,646,700 shares outstanding.
What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?
Radiopharm Theranostics Limited reported an EPS of -AU$0.052 in its last earnings report, missing expectations of -AU$0.01. Following the earnings report the stock price went up 33.333%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?
Currently, no hedge funds are holding shares in AU:RAD
---
Radiopharm Theranostics Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.40 (1233.33% Upside)
AU$0.40 (1233.33% Upside)
Blogger Sentiment
Bullish
AU:RAD Sentiment 77%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth AU$14.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.53%
12-Months-Change
Fundamentals
Return on Equity
-132.26%
Trailing 12-Months
Asset Growth
-3.89%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited
Radiopharm Theranostics Ltd is a clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development.
---
RAD Stock 12 Month Forecast
Average Price Target
AU$0.40
▲(1233.33% Upside)
Technical Analysis
Best Analysts Covering RAD
1 Year
1 Year Success Rate
3/5 ratings generated profit
1 Year Average Return
-17.12%
reiterated a buy rating 3 months ago
Copying Justin Walsh's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -17.12% per trade.
---